Curis, Inc. company was founded in 2000 and is based in Cambridge, Massachusetts. Curis, Inc., a drug discovery and development company, focuses on the research and development of cancer therapeutics. The company, in collaboration with Genentech, is conducting a pivotal Phase II clinical trial on its lead molecule, GDC-0449 in advanced basal cell carcinoma patients, as well as various Phase II clinical trials in first-line metastatic colorectal cancer and in advanced ovarian cancer patients. It is also evaluating CUDC-101, a small molecule that is in a Phase I clinical testing and is designed to target histone deacetylase (HDAC), epidermal growth factor receptor (EGFR), and epidermal growth factor receptor 2 (Her2). In addition, Curis has a development candidate, CUDC-305, a Heat Shock Protein 90 (Hsp90) inhibitor.

Apex Healthcare Berhad Company makes, markets, and distributes generic pharmaceuticals and other health care products to customers in Malaysia, Singapore, Indonesia, and China. Subsidiary Xepa-Soul Pattinson (Xepa SP), the company's manufacturing arm, is Malaysia's largest generic drug maker with products including antibiotics, corticosteroids, and neuromuscular agents in tablet, capsule, liquid, cream, and powder formulations. Xepa-SP also makes nutritionals (vitamins) and surgical supplies. The company distributes its own products and those of other manufacturers to wholesale and retail customers through subsidiaries ABio, Apex Pharmacy Marketing, and Apex Pharma.

Nycomed US Inc. (formerly Altana Inc) is a subsidiary of Nycomed, which operates three divisions in the US focused on specialty pharmaceuticals in dermatology. Founded in 1849, Fougera is the largest of the three divisions and is a leading manufacturer and distributor of a wide range of multi-source topical steroids, antibiotics and antifungal products. The PharmaDerm division of Nycomed is dedicated to bringing innovative products to the dermatologists so they can best care for their patients. Nycomed US also markets and sells Savage Laboratories products, which focus on emergency care.

Biotie is a drug discovery and development company focused on central nervous system and inflammatory diseases. It has a broad range of innovative small molecule and biological drug candidates at different stages of clinical and pre-clinical development. Biotie’s products address diseases with high unmet medical need and significant market potential, including addiction and psychotic disorders, rheumatoid arthritis, psoriasis and chronic obstructive pulmonary disease (COPD). The most advanced product, nalmefene for alcohol dependence, is currently in phase III clinical development by licensing partner H. Lundbeck A/S. The commercial value of the pipeline has been demonstrated through existing alliances with top-tier global pharmaceutical companies such as Lundbeck, Roche and Pfizer. Biotie has operations in Turku, Finland and Radebeul, Germany.

Since its establishment in 1982, Orgenics' objective has been to develop accurate and safe diagnostic products for serious and life-threatening conditions and diseases. Orgenics contributes to the increased awareness and early detection of HIV, infectious diseases, pregnancy and fertility, respiratory diseases, cancer and cardiology through clinical and point-of-care diagnostics. Orgenics delivers products and solutions to partners and customers in over 150 countries around the globe.Orgenics unique and patented ImmunoComb® technology is quick and easy to use, providing high sensitivity and specificity. Instrument free Orgenics' ImmunoComb® kits are ideal for decentralized clinical laboratories, field hospitals and remote rural areas. Orgenics' ImmunoLISA™ system is based on classic ELISA assay principle and is suitable for any laboratory setting.

Pain Therapeutics, Inc. was founded in 1998 and is based in San Mateo, California. Pain Therapeutics, Inc., a biopharmaceutical company, engages in the research and development of novel drugs. It has four drug candidates in clinical development programs, which include Remoxy, a novel controlled-release oral capsule form of oxycodone; PTI-202 and PTI-721, which are abuse-resistant forms of opioid drugs; and PTI-188 for the treatment of metastatic melanoma. The company is also developing a technology for the treatment of hemophilia in patients. Pain Therapeutics, Inc. has a strategic alliance with King Pharmaceuticals, Inc. for the development and commercialization of Remoxy, PTI-202, PTI-721, and other abuse-resistant opioid painkillers.

Metagenics, Inc., doing business as Ethical Nutrients, manufactures and distributes medical foods and nutraceuticals to healthcare practitioners. The company offers FirstLine Therapy programs for the prevention and management of chronic conditions, including diabetes, cardiovascular disease, and arthritis. It distributes its products in North America, South America, Europe, and Asia. The company was founded in 1983 and is headquartered in San Clemente, California with research and development centers in Gig Harbor, Washington; and Ithaca, New York. It has manufacturing facilities in Gig Harbor, Washington. As of September 11, 2009, Metagenics, Inc. operates as a subsidiary of Alticor Inc.

China Shenghuo Pharmaceutical Holdings, Inc. (Shenghuo) is primarily engaged in the research, development, manufacture, and marketing of pharmaceutical, nutritional supplement and cosmetic products. Almost all of its products are derived from the medicinal herb Panax notoginseng, also known as Sanqi, Sanchi or Tienchi. Its main product, Xuesaitong Soft Capsules, accounted for more than 87% of its sales for the year ended December 31, 2008. Xuesaitong Soft Capsules are primarily sold in China, but the product is also sold in various developing countries, including Malaysia, Indonesia and Kyrgyzstan. Panax notoginseng saponins (PNS), the active ingredient in Panax notoginseng, is extracted from the plant using high-tech equipment and in accord with Good Manufacturing Practice (GMP) standards.

Actavis U.S. is the US manufacturing and marketing unit of global generics firm Actavis. The company makes a wide variety of generic equivalents of both prescription and OTC drugs, in a number of forms, including liquids, tablets, creams, and suppositories. Among other consumer and specialty drugs, it makes acetaminophen, ibuprofen, and generic Rogaine. It has also launched generic versions of Pfizer's diabetes drug Glucotrol XL and GlaxoSmithKlein's Coreg tables for hypertension and myocardial infarction. Actavis U.S. has manufacturing facilities in Maryland, New Jersey, and North Carolina, from which it ships its own products and provides contract manufacturing services to third parties.

Solgar has been innovating and producing fine quality nutritional supplements since 1947. Our ongoing mission is to provide consumers with top-quality, innovative, science-based nutritional supplements to enhance their total health and well-being. We are committed to exclusively distributing our products in the natural products industry where knowledgeable retailers worldwide can guide consumers through the vast array of choices.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.